As of June 13, 2025, ARCA Biopharma Inc (ABIO) reports a Current Ratio of 59.01.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of ARCA Biopharma Inc's Current Ratio
Over recent years, ARCA Biopharma Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2023-12-31 | 59.01 |
| 2022-12-31 | 37.72 |
| 2021-12-31 | 15.56 |
| 2020-12-31 | 14.29 |
| 2019-12-31 | 9.44 |
This steady improvement highlights how ARCA Biopharma Inc manages its short-term assets and liabilities over time.
Comparing ARCA Biopharma Inc's Current Ratio to Peers
To better understand ARCA Biopharma Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| ARCA Biopharma Inc (ABIO) | 59.01 |
| Forward Pharma A/S (FWP) | 117.44 |
| Rezolute Inc (RZLT) | 13.39 |
| Ocuphire Pharma Inc (OCUP) | 13.35 |
| PharmaCyte Biotech Inc (PMCB) | 6.80 |
| Brickell Biotech Inc (BBI) | 6.15 |
Compared to its competitors, ARCA Biopharma Inc's Current Ratio is among the highest compared to peers, indicating strong short-term financial flexibility but potentially excess cash that could be invested.